Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors’ reply

Detalles Bibliográficos
Autores principales: Cortegiani, A., Ippolito, M., Einav, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577672/
https://www.ncbi.nlm.nih.gov/pubmed/33158787
http://dx.doi.org/10.1016/j.pulmoe.2020.10.003
_version_ 1783598222429650944
author Cortegiani, A.
Ippolito, M.
Einav, S.
author_facet Cortegiani, A.
Ippolito, M.
Einav, S.
author_sort Cortegiani, A.
collection PubMed
description
format Online
Article
Text
id pubmed-7577672
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U.
record_format MEDLINE/PubMed
spelling pubmed-75776722020-10-22 Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors’ reply Cortegiani, A. Ippolito, M. Einav, S. Pulmonology Letter to the Editor Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. 2021 2020-10-21 /pmc/articles/PMC7577672/ /pubmed/33158787 http://dx.doi.org/10.1016/j.pulmoe.2020.10.003 Text en © 2020 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Cortegiani, A.
Ippolito, M.
Einav, S.
Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors’ reply
title Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors’ reply
title_full Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors’ reply
title_fullStr Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors’ reply
title_full_unstemmed Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors’ reply
title_short Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors’ reply
title_sort rationale and evidence on the use of tocilizumab in covid-19: a systematic review. authors’ reply
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577672/
https://www.ncbi.nlm.nih.gov/pubmed/33158787
http://dx.doi.org/10.1016/j.pulmoe.2020.10.003
work_keys_str_mv AT cortegiania rationaleandevidenceontheuseoftocilizumabincovid19asystematicreviewauthorsreply
AT ippolitom rationaleandevidenceontheuseoftocilizumabincovid19asystematicreviewauthorsreply
AT einavs rationaleandevidenceontheuseoftocilizumabincovid19asystematicreviewauthorsreply

Ejemplares similares